PremiumThe FlyOrganogenesis backs FY25 revenue view $480M-$535M, consensus $549.3M CMS reviewing coverage policies for skin substitute products Organogenesis Highlights Strategic Focus in Investor Presentation PremiumCompany AnnouncementsOrganogenesis Holdings Reports Strong Q4 2024 Results Organogenesis sees FY25 revenue $480M-$535M, consensus $472.94M Organogenesis reports Q4 EPS 4c, consensus 2c PremiumCompany AnnouncementsOrganogenesis Holdings Secures $130M Investment for Growth Organogenesis Reports Robust Third Quarter Growth Organogenesis reports Q3 EPS 9c, consensus (1c)